Ted Skolarus to Prostatic Neoplasms, Castration-Resistant
This is a "connection" page, showing publications Ted Skolarus has written about Prostatic Neoplasms, Castration-Resistant.
Connection Strength
3.290
-
Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. Cancer Med. 2024 Jun; 13(12):e7334.
Score: 0.826
-
Differential adoption of castration-resistant prostate cancer treatment across facilities in a national healthcare system. Cancer Med. 2023 03; 12(6):6945-6955.
Score: 0.755
-
Factors influencing treatment of veterans with advanced prostate cancer. Cancer. 2021 07 01; 127(13):2311-2318.
Score: 0.662
-
Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. J Oncol Pract. 2017 08; 13(8):e694-e702.
Score: 0.510
-
Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant Prostate Cancer in a National Health Care Delivery System. JCO Oncol Pract. 2024 01; 20(1):59-68.
Score: 0.198
-
Mental health care utilization among men with castration-resistant prostate cancer receiving abiraterone or enzalutamide. Cancer Med. 2023 08; 12(15):16490-16501.
Score: 0.193
-
Adoption of Abiraterone and Enzalutamide by Urologists. Urology. 2019 09; 131:176-183.
Score: 0.146